63% of Americans expect injectable weight-loss drugs to keep gaining users
Core finding
In a Verasight survey conducted Aug. 1-6, 2025, nearly two-thirds of Americans (63%) expect the use of injectable weight-loss drugs like Ozempic to keep climbing beyond current levels.
About one-in-five (18%) do not, and a similar share (19%) are unsure.
Topline distribution
63% of Americans expect injectable weight-loss drugs to keep gaining users.
In your opinion, will the use of injectable weight loss drugs (like Ozempic) continue to grow, beyond it's current level of use?
n = 1,000 · Aug 1–6, 2025 · MoE ±3.2%
Methodology
Full methodology →| Mode | Verasight panel recruited via random address-based sampling, random person-to-person text messaging, and dynamic online targeting |
|---|---|
| Population | United States adults |
| Field dates | Aug 1–6, 2025 |
| Base (unweighted) | 1,000 |
| Margin of error | ±3.2% |
| Module | B |
| Sponsor | Verasight |
| Weight variable | weight |
| Weighting targets | age, race/ethnicity, sex, income, education, region, metropolitan status |
Sources
- verasight-quirks-2025.tiiny.co
In your opinion, will the use of injectable weight loss drugs (like Ozempic) continue to grow, beyond it's current level of use?
Cite this question
Verasight Quirks Omnibus Survey, fielded August 1-6, 2025, N=1,000 United States adults, +/- 3.2%.